Multi-Drug Resistance

Deadline: 2020-03-31
Award: €1,000,000
Open to: Everyone*

Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections. CDC estimates that in the United States, more than two million people are sickened every year with antibiotic-resistant infections, with at least 23,000 dying as a result.

There are high proportions of antibiotic resistance in bacteria that cause common infections (e.g. urinary tract infections, pneumonia, bloodstream infections) in all regions of the world. A high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Gram-negative bacteria.

The dream product is a series of novel narrow-spectrum antibacterial agents that are able to cure any bacterial infection without induction of drug resistance, empowered by a one hour diagnostic test.

The Future Insight Prize puts the vision for ambitious dream products of global importance for humankind into the world and triggers curiosity and creativity on how to make these visions a reality.